NASDAQ:AVTX

Avalo Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy AVTX

*Your capital is at risk

$17.08

+2.38 (+16.19%)

At Close: Jun 22, 2026

Avalo Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -36.68. In total, the insiders bought 1.92M and sold 353.44K AVTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-36.68
● Buy	1.92M shares
● Sell	353.44K shares
63% Buy Activity Moderate Negative Correlation
Sell Signal Medium Confidence May 06, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -36.68. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 10, 2026 Sell	Common Stock F-InKind	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	138 Value: $2K
Jun 10, 2026 Sell	Common Stock F-InKind	Varki Paul Chief Legal Officer	Officer	1 081 Value: $14.2K
Jun 10, 2026 Sell	Common Stock F-InKind	Riley Jennifer Chief Strategy Officer	Officer	588 Value: $8K
Jun 10, 2026 Sell	Common Stock F-InKind	Doyle Mittie Chief Medical Officer	Officer	1 084 Value: $14.2K
Jun 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Kaplan Gilla Director	Director	20 100 Value: $280.6K
Jun 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Truex Samantha Director	Director	20 100 Value: $280.6K
Jun 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Jain Rita Director	Director	20 100 Value: $280.6K
Jun 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Lind Kevin Robert Director	Director	20 100 Value: $280.6K
Jun 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Kantoff Aaron Director	Director	20 100 Value: $280.6K
Jun 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Heffernan Michael Thomas Director	Director	29 500 Value: $411.8K
May 28, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Doyle Mittie Chief Medical Officer	Officer	679 Value: $5K
May 28, 2026 Buy	Common Stock M-Exempt	Doyle Mittie Chief Medical Officer	Officer	679 Value: $5K
May 28, 2026 Sell	Common Stock S-Sale	Doyle Mittie Chief Medical Officer	Officer	679 Value: $10.9K
May 21, 2026 Buy	Common Stock A-Award	Neil Garry Arthur Chief Executive Officer	CEO / President	100 200 Value: $1.66M
May 21, 2026 Buy	Common Stock A-Award	Doyle Mittie Chief Medical Officer	Officer	43 500 Value: $722.1K
May 21, 2026 Buy	Common Stock A-Award	Riley Jennifer Chief Strategy Officer	Officer	34 200 Value: $567.7K
May 21, 2026 Buy	Common Stock A-Award	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	39 900 Value: $662.3K
May 21, 2026 Buy	Common Stock A-Award	Varki Paul Chief Legal Officer	Officer	24 300 Value: $403.4K
May 15, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Doyle Mittie Chief Medical Officer	Officer	3 000 Value: $38.0K
May 15, 2026 Buy	Common Stock M-Exempt	Doyle Mittie Chief Medical Officer	Officer	3 000 Value: $38.0K
May 15, 2026 Sell	Common Stock S-Sale	Doyle Mittie Chief Medical Officer	Officer	3 000 Value: $56.3K
May 07, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	18 606 Value: $183.8K
May 07, 2026 Buy	Common Stock M-Exempt	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	18 606 Value: $183.8K
May 07, 2026 Sell	Common Stock S-Sale	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	18 606 Value: $448.8K
May 06, 2026 Sell	Common Stock S-Sale	Chan Mitchell Director	Director	3 167 Value: $72.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AVALO THERAPEUTICS, INC.

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe...

Read Full Profile Here